Kornimate/medical-research-clean huggingface dataset:
a study of il4rα monoclonal antibody in patients with seasonal allergic rhinitis(sar).

Conditions: Allergic Rhinitis

Summary: allergic rhinitis (ar) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin e after exposure to allergens in atopic individuals. the typical symptoms of ar are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. bronchial asthma is associated with bronchial asthma in 40% of patients with ar, suggesting a comorbid feature of allergic disease.


Eligibility criteria:
main inclusion criteria: 1. voluntarily sign the informed consent form. 2. seasonal allergic rhinitis has been prevalent for at least 2 years. 3. poor control of seasonal allergic rhinitis with nasal glucocorticoids or other therapeutic agents during the same pollen season in the past. 4. positive spt or serum-specific ige test results. 5. symptom severity scores for the season met the enrollment criteria. main exclusion criteria: 1. other nasal comorbidities or co-morbidities/states that may be present at the time of screening that affect efficacy determination. 2. subjects whose allergen exposures in their home or work environments may be expected to change significantly during the trial period. 3. subjects with poorly controlled recent asthma conditions. 4. presence of current or past history of infection of special concern, e.g., active tuberculosis, helminthic infections, severe herpes virus infections, etc. 5. previous use of anti-interleukin 4 receptor alpha subunit (il4rα) monoclonal antibody. 6. have a serious underlying medical condition that, in the opinion of the investigator, may pose a risk to subject safety by participation in a clinical trial.
evolution of swallowing in patients undergoing lateral pharyngoplasty with preservation stylopharyngeal muscle

Conditions: Sleep Apnea

Summary: evolution of swallowing in patients undergoing lateral pharyngoplasty with preservation stylopharyngeal muscle.

refer patients to the side pharyngoplasty with total preservation of stylopharyngeal muscle and evaluate the total recovery time of swallowing, making a daily assessment.

Eligibility criteria:
inclusion criteria: * patients with obstructive sleep apnea with surgical indication exclusion criteria: * patients with obstructive sleep apnea without surgical indication

Keywords: sleep apnea, obstructive deglutition disorders
study evaluating the safety, in terms of hbv virological control at 96 weeks, of 2 antiviral treatment relief strategies, in patients co-infected with the hiv-1 and hbv viruses

Conditions: HIV Infections; HBV Coinfection

Summary: the main objective of this study is to evaluate at 96 weeks the safety with respect to hepatitis b control of 2 treatment reduction strategies for patients with previously controlled hiv-hbv co-infection on continuous triple therapy


Eligibility criteria:
inclusion criteria: 1. hiv-1-hbv co-infection (positive hiv-1 serology associated with 2 positive hbsag serologies within more than 6 months); 2. age ≥ 18 years 3. fibroscan less than 6 months \< 9kpa 4. current daily antiretroviral tritherapy not modified for ≥ 12 months must including tenofovir disoproxil fumarate (tdf) 245mg or tenofovir alafenamide fumarate (taf -25mg) associated to lamivudine (3tc - 300mg) or emtricitabine (ftc - 200mg) and a nnrti or pi/r or insti to choose from * nnrti = efavirenz, rilpivirine, etravirine, doravirine * pi/r = atazanavir/r ou darunavir/r * insti = bictegravir, dolutegravir, elvitegravir/cobicistat, raltegravir; 5. absence of documented hbv and hiv genotypic resistance compromising virologic control of any of the maintenance strategies. patients with no genotypic history may be included); 6. hiv cv \< 50cp/ml for ≥ 2 years (only 1 annual blip allowed if hiv cv \< 200cp/ml and previous and subsequent viral loads are undetectable); 7. hbv cv \< 10 iu/ml for ≥ 2 years (only 1 annual blip allowed if hbv cv \< 200iu/ml and if previous and subsequent viral loads are undetectable); 8. have ≥ 3 available measurements of hiv cv \< 50cp/ml and hbv cv \< 10 iu/ml over the past 24 months (including that of pre-inclusion); 9. cd4 lymphocytes \> 250/mm3 at pre-inclusion; 10. alt \< 3n at pre-inclusion; 11. for women of childbearing potential, negative pregnancy test and commitment to use effective contraception throughout the trial; 12. person affiliated with or benefiting from a social security system; 13. free, informed, written consent, signed by the person and the investigator at the latest on the day of inclusion and before any examination carried out as part of the study (article l1122-1-1 of the public health code) exclusion criteria: 1. hiv-2 infection; 2. hiv and/or hbv genotype not compatible with dual therapy dtg-3tc or drvr-3tc; 3. hbeag+; 4. fibrosis history at stage f3-f4 in pre-therapy evaluated by pbh, fibrotest and/or fibroscan with a value of elastometry ≥ 9kpa; 5. chronic active viral hepatitis c (hcv rna positive); 6. delta co-infection; 7. alcohol consumption \> 14 units/week for women and 21 units/week for men; 8. current treatment with chemo- or immunotherapy (including interferon or interleukins); 9. active opportunistic infection or acute treatment for opportunistic infection; 10. any condition (drug use, neurological, neuropsychiatric, etc.) that, in the judgment of the investigator, may compromise patient compliance and adherence to the protocol; 11. pregnant or breastfeeding woman or refusal of contraception; 12. major incapacity, legal protection, guardianship or curatorship
pharmacodynamics of omiganan bid in patients with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this study has a randomized, double-blind, placebo-controlled design to assess the efficacy, pharmacodynamics and safety/tolerability of omiganan in patients with mild to moderate atopic dermatitis when applied bid to all atopic dermatitis lesions.


Eligibility criteria:
inclusion criteria: * male and female subjects with mild to moderate ad (iga 2 or 3) 18 to 65 years of age,inclusive. the health status is verified by absence of evidence of any clinical significant active or uncontrolled chronic disease other than ad following a detailed medical history, a complete physical examination including vital signs, 12-lead ecg, hematology, blood chemistry, virology and urinalysis; * confirmed ad diagnosis; * symptoms present for at least 1 year; * easi between 7.1 - 50.0, inclusive at screening; * 2-20% body surface area (bsa) affected at screening; * body mass index (bmi) between 18 and 35 kg/m2, inclusive, and with a minimum weight of 50 kg; * able to participate and willing to give written informed consent and to comply with the study restrictions; * subjects and their partners of childbearing potential must use effective contraception, for the duration of the study and for 3 months after the last dose. exclusion criteria: * any current and / or recurrent clinical significant skin condition other than ad; * pregnant, a positive pregnancy test, intending to become pregnant, or breastfeeding; * ongoing use of prohibited atopic dermatitis treatments. requires washout period prior to baseline (first dose of the study drug); * use of topical medication (prescription or over-the-counter \[otc\]) within 14 days of study drug administration, or less than 5 half-lives (whichever is longer) in local treatment area; * tanning due to sunbathing, excessive sun exposure or a tanning booth within 3 weeks of enrollment; * known hypersensitivity to the compound or excipients of the compound or known hypersensitivity to one or more different emollients; * participation in an investigational drug or device study within 3 months prior to screening or more than 4 times a year; * loss or donation of blood over 500 ml within three months (males) or four months (females) prior to screening.
use of low dose of hcg during ovulation induction with cc in women with cc resistant pcos

Conditions: Infertility; Polycystic Ovarian Syndrome

Summary: the purpose of this study is to evaluate the effect of administration of low dose of human chorionic gonadotropin (hcg) after use of clomiphene citrate (cc) for induction of ovulation in infertile women having cc resistant polycystic ovarian syndrome (pcos).

women will be randomly divided into two groups; cc-hcg group and cc group. women in the cc-hcg group will receive cc (150 mg/day for 5 consecutive days from day 2 of cycle) and hcg (200 iu/day sc from day 7 of cycle). women in the cc group will receive cc alone (150 mg/day for 5 consecutive days from day 2 of cycle). transvaginal sonography (tvs) scan will be performed regularly for monitoring of follicular growth (folliculometry); starting from day 10 of the stimulation cycle and repeated every 2-3 days. when there will be at least one follicle ≥ 18 mm in diameter, final oocyte maturation will be induced by intramuscular administration of 10000 iu of hcg and timed intercourse will be advised. if there will be no follicle ≥ 12 mm by day 16 of the cycle, monitoring of follicular growth will be discontinued and the cycle will be presumed to be anovulatory. ovulation will be documented by tvs scan one week after triggering of oocyte maturation and will be confirmed by assessing the midluteal serum progesterone level. each woman will be subjected to ovarian stimulation for a maximum of 3 consecutive cycles except if she gets pregnant in the first or second cycle

Eligibility criteria:
inclusion criteria: * infertile lean women with pcos as defined by the rotterdam criteria. * cc resistance (defined as failure of ovulation after receiving 150 mg/day of cc for 5 consecutive days per cycle, for at least 3 consecutive cycles). exclusion criteria: * age \ 35 years. * presence of any infertility factor other than anovulatory pcos. * previous history of ovarian surgery or surgical removal of one ovary. * previous exposure to cytotoxic drugs or pelvic irradiation. * oral hypoglycemic or hormonal therapy either currently or in the preceding 3 months. * metabolic or hormonal abnormalities.

Keywords: pcos clomiphene citrate resistant hcg
comparison of gene mutations in matched samples in advanced nonsquamous nsclc using ngs

Conditions: Lung Cancer

Summary: the objective of the study was to compare the gene mutation status among the primary tumor, matched metastatic lymph node (ln) and peripheral blood in advanced nonsquamous non-small cell lung cancer (nsclc) using next-generation sequencing (ngs).

many gene mutations have been detected in lung cancer, which might differ between the primary tumor and the metastases in a same patient. one may cause by the heterogenicity of the tumor, another may cause by the sensitivity of the detection technique. so we determine to use ngs, which is a more sensitive technique, to detect the different gene mutations among the primary tumor, metastatic ln and peripheral blood in advanced nonsquamous nsclc. the study was designed as a prospective and single center study. thirty five patients will be enrolled into the study and the clinical data of the patients, including his smoke history, cancer history, occupation exposure and so on, will be collected and recorded in a case report form. for the patients recruited in the study, the primary tumor and metastatic lymph nodes will be obtained by interventional pulmonology technology. and about 10ml peripheral blood will be collected at the same time. the tissue will be sent to pathology department of shanghai chest hospital and will be processed with paraffin-embedded, and for those diagnosed with nonsquamous nsclc, the rest tissue will be extracted with dna and performed ngs for the qualified dna sample using illumina nextseq500 sequencer.the matched peripheral blood will also be extract with dna and performed ngs using illumina nextseq500 sequencer.

Eligibility criteria:
inclusion criteria: 1. patients who are suspected with nonsquamous non-small cell lung cancer according to the clinical, lab examination and imaging data and had never been diagnosed as primary lung cancer before will be enrolled into the study. 2. the clinical stage of the patients should be in stage iiia-iv judged by the imaging data and can't receive surgery initially, 3. there exist at least one primary tumor and at least one enlarged ln which can be biopsied by minimally invasive techniques. exclusion criteria: 1. the patient is highly suspected to benign lesion, small cell lung cancer and squamous cell carcinoma according to the clinical data. 2. surgery was considered to be the primary treatment. 3. patients who are diagnosed with lung cancer and received treatment with drugs or recurrent with lung cancer will be excluded.

Keywords: gene testing next-generation sequecing primary tumor metastatic lymph node peripheral blood
effect of resistance training in water combined with land on starting and turning ,12-weeks resistance training

Conditions: Resistance, APC

Summary: resistance training has been widely used in various sports and is a common practice aimed at improving competition performance, especially in swimming. swimming performance is highly dependent on muscle strength, especially short distances. water or land resistance training can improve the swimming performance, especially the swimming performance of 50 meters and 100 meters. both type of training has their own strength and weakness. hence, combining both methods strength may enhance swimmer performance. in addition, competitive swimming consists of different stages, namely start, clean swim, turn and finish. however, there is no literature on the influence of resistance training on starting and turning.

through experimental design and quantitative research methods. in this experiment, the resistance training method of water combined with land was used to intervene the turning and starting of young people, and the traditional strength training was compared to find out a better training method. the experiment will use 12 weeks of resistance training to improve the swimmer's turn and start intervention. the experiment consisted of four groups, 20 boys and 20 girls in the experimental group and 20 boys and 20 girls in the control group. compare the differences between the two groups. divided into discussion groups and general teaching groups. two of the most significant differences, this experiment aims to provide a theoretical basis for improving the training methods of swimming, so that young swimmers can get better swimming performance, especially on the start and turn. experiment group week1-3: drag umbrella , resistance bands, swiss ball, hand resistance. week3-6: drag umbrella , resistance bands, swiss ball, hand resistance. week6-9: drag umbrella, pulley pull, medicine ball, resistance suit. week9-12: drag umbrella pulley pull, medicine ball, resistance suit. control group week1-3: sit-up, press-up, deep squat, lift heel week 3-6: sit-up, press-up, deep squat, lift heel week6-9: dumbbell, barbell ,stomach up, squat up week9-12: dumbbell, barbell, stomach up, squat up

Eligibility criteria:
inclusion criteria: 1. swimmers participate in organized swimming training programs. 2. participants with an average age of about 10 years. exclusion criteria: 1. untrained, novice, masters, and paraplegic swimmers. 2. triathlon and water polo athletes. 3. injured swimmers.

Keywords: resistance training starting turning performance adolescent
envarsus in delayed graft function (e-dgf)

Conditions: Delayed Graft Function

Summary: envarsus xr is an extended release tacrolimus designed to deliver tacrolimus more consistently, thus avoiding large fluctuations of tacrolimus trough levels with envarsus xr compared to immediate release tacrolimus. it is expected that patients with dgf on envarsus xr will have more stable tacrolimus levels and facilitate early recover from dgf compared to immediate release tacrolimus.

this is a single center randomized phase iv trial of comparing extended release envarsus xr (study drug) once a day vs immediate release tacrolimus twice a day in a new kidney transplant recipients with delayed graft function (dgf). the primary study endpoint is the interval between first dialysis and last dialysis after kidney transplant (duration of dgf). the second end point is the number of tacrolimus or envarsus xr dose adjustments required during the period of dgf.

Eligibility criteria:
inclusion criteria: 1. willing and able to provide written informed consent 2. willing to comply with all study procedures and be available for the duration of the study 3. male or female, at least 18 years of age 4. documented diagnosis of dgf or need for dialysis or had dialysis within the first week of kidney transplant 5. current treatment with tacrolimus based regimen or planned to start tacrolimus based immunosuppressive regimen 6. females of childbearing potential must have a negative urine or serum pregnancy test prior to randomization and agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to randomization, for the duration of study participation, and for 7 days following completion of therapy. * a female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: * has not undergone a hysterectomy or bilateral oophorectomy; or * has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). exclusion criteria: 1. history of hypersensitivity or allergy to any of the study drugs or drugs of similar chemical classes 2. current use of non-tacrolimus based immunosuppressive regimen or no plan to start tacrolimus based regimen 3. women who are or plan to become pregnant or breast-feeding during the study period 4. not suitable for study participation due to other reasons at the discretion of the investigator 5. major post-surgical complications requiring allograft nephrectomy 6. multi-organ transplant recipients 7. non kidney transplant recipients

Keywords: kidney transplant
short-term outcome of medical vs. surgical management of chronic anal fissure

Conditions: Anal Fissure Chronic

Summary: several topical agents have been proposed for chronic anal fissure (caf) treatment with the common goal of increasing anodermal blood flow to promote healing but approaching the use of medical treatment in cafs is not standardized yet. thus, the present study aimed to compare the efficacy and safety of sucralfate (emoflon®), the combination of azadirachtin and hyperforin (hyperoil®) and the traditional surgical treatment (lateral sphincterotomy) in patients with cafs.

several topical agents have been proposed for chronic anal fissure (caf) treatment with the common goal of increasing anodermal blood flow to promote healing but approaching the use of medical treatment in cafs is not standardized yet. thus, the present study aimed to compare the efficacy and safety of sucralfate (emoflon®), the combination of azadirachtin and hyperforin (hyperoil®) and the traditional surgical treatment (lateral sphincterotomy) in patients with cafs. study objective: primary objectives: 1. to evaluate the efficacy and safety of sucralfate (emoflon®), the combination of azadirachtin and hyperforin (hyperoil®) and the traditional surgical treatment (lateral sphincterotomy) in patients with cafs. study design: a prospective randomized controlled trial study sampling: a convenience sampling method will be used; all patients seeking medical advice for caf at suez canal university hospitals, the faculty of medicine during the study period and fulfill the inclusion criteria will be recruited. one of the researchers who will make random allocation cards using an excel formula algorithm will perform simple randomisation. methodology: this study will include at least 99 patients with cafs of both genders who will visit the general surgery clinic in the faculty of medicine at suez canal university hospital and fulfil the inclusion and exclusion starting from september 2024. patients of both genders with caf for the first time, above 18 years old and asa i/ii will be included in the study. while patients with sepsis, previous pelvic radiation, recurrent caf, with malignancy, on immunosuppressive drugs, with pregnancy or lactation will be excluded. patients will be randomly allocated into 3 groups at a ratio of 1:1:1 starting with the sucralfate group. formal written consent will be obtained from the study participants prior to being involved in the study. all included patients will be followed up to 40 days.

Eligibility criteria:
inclusion criteria: * above 18 years old. * cafs for the first time * asa i, ii exclusion criteria: * sepsis * previous pelvic radiation. * recurrent chronic anal fissure * pregnancy or lactation. * immunosuppressive state * malignancy * refusal to participate

Keywords: chronic anal fissure
triheptanoin (c7 oil), a food supplement, for glucose transporter type i deficiency (g1d)

Conditions: Glucose Transporter Type 1 Deficiency Syndrome; Glut1 Deficiency Syndrome

Summary: this is a single-site, open-label, phase ii trial of c7, a food supplement or medical food, for the development of treatment outcome measures for glucose transporter type i deficiency (g1d). the primary outcome measures are: 1. safety and tolerability of c7 as measured by changes in comprehensive blood work, including lipid and free fatty acid panels, self-reported side effects and clinical exam; 2. changes in brain metabolic rate by mri and eeg measurements during c7 treatment; and 3. maintenance of ketosis in g1d patients on ketogenic diet, as measured by serial ketone levels during treatment initiation.


Eligibility criteria:
inclusion criteria: * diagnosis or suspected diagnosis of glucose transporter type i deficiency (g1d). * on stable ketogenic diet at a ratio between 1:2.5 and 1:4 or stable on no dietary therapy * males and females 30 months to 55 years old, inclusive. exclusion criteria: * subjects with a history of life-threatening seizure episodes, including but not limited to status epilepticus and cardiac arrest. * subjects with a bmi (body mass index) greater than or equal to 30 will be excluded. * subjects currently on dietary therapy other than ketogenic diet (i.e., medium chain triglyceride-supplemented diets, atkins diet, low glycemic index diet, etc.). * women who are pregnant or breast-feeding may not participate. women who plan to become pregnant during the course of the study, or who are unwilling to use birth control to prevent pregnancy (including abstinence) may not participate. * allergy/sensitivity to triheptanoin. * previous treatment with triheptanoin. * treatment with medium chain triglycerides in the last 30 days. * subjects exhibiting signs of dementia, or diagnosed with any degenerative brain disorder (such as alzheimer's disease) that would confound assessment of cognitive changes, in the opinion of the investigator. * active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements. * patients with metal implants, experience claustrophobia, or who are behaviorally unable to be still for mrs (magnetic resonance spectroscopy) imaging (not due to seizures) will be excluded from the imaging portion of the research. * inability or unwillingness of subject or legal guardian/representative to give written informed consent, or assent for children age 10-17.

Keywords: g1d glut1 deficiency glucose transporter type 1 deficiency glucose transporter type i deficiency